This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Empagliflozin
SGLT2 Inhibitor | Diabetes, Heart Failure, CKD, Longevity Candidate
Aliases (5)
Overview
What is Empagliflozin?
Empagliflozin (Jardiance) is a sodium-glucose cotransporter-2 (SGLT2) inhibitor FDA-approved 2014 for type 2 diabetes, then expanded to heart failure with reduced ejection fraction (2021), heart failure with preserved ejection fraction (2022), and chronic kidney disease (2023). Increasingly discussed alongside metformin and rapamycin as a top-tier candidate for off-label longevity research, though no aging-prevention RCT has yet been run.
Key Benefits
Lowers HbA1c without hypoglycemia, drives 2-3 kg weight loss via daily glucosuria, reduces cardiovascular death by 38% (EMPA-REG OUTCOME), reduces heart-failure hospitalization regardless of diabetes status (EMPEROR), slows CKD progression (EMPA-KIDNEY), modestly lowers BP and uric acid. The most extensively studied geroscience-adjacent drug after metformin.
Mechanism of Action
Selectively inhibits SGLT2 in the proximal renal tubule, blocking ~90% of filtered glucose reabsorption. The kidney excretes ~70-80 g glucose/day (~280 kcal). This drives mild caloric loss, osmotic diuresis (volume contraction), natriuresis (BP drop), uric acid excretion, and metabolic substrate-switching toward fatty acids and ketones — the latter hypothesized to underpin the cardiac and renal protection seen across HF/CKD trials. Cardio-renal benefit is partially independent of glycemic effect: HFrEF, HFpEF, and CKD trials all confirmed efficacy in non-diabetics.
Pharmacokinetics
Peptide Interactions
Combined as Synjardy (FDA-approved fixed-dose). Different mechanisms — empagliflozin blocks renal glucose reabsorption, metformin suppresses hepatic gluconeo…
Combined as Glyxambi. Complementary glucose-lowering with low hypoglycemia risk; DPP-4i raises endogenous GLP-1, SGLT2i drives glucosuria.
Increasingly co-prescribed. Additive glycemic + cardiovascular benefit. Different mechanisms (incretin vs renal). Well-tolerated combination; CKD/HF benefit …
Standard combination in HF and CKD. Both reduce renal RAS activation; SGLT2i adds tubuloglomerular feedback restoration. Complementary, no interaction.
HFrEF triple therapy. Monitor potassium.
Different mechanisms (mTOR vs renal glucose). No interaction data in humans. Mechanistically additive on autophagy/longevity pathways.
Increases euglycemic DKA risk substantially. Hold drug during these states.
Compounds dehydration, raises DKA risk, worsens hypoglycemia in stacked regimens.
Additive natriuresis and volume contraction; reduce diuretic dose at SGLT2i initiation, especially in HF.
Hold 48 hours pre/post for contrast CT; AKI risk in volume-depleted state.
Hypoglycemia risk additive; reduce these doses 10-20% when adding SGLT2i.
Additive BP drop; may need dose reduction.
Quality Indicators
Pharmacy-dispensed branded or generic
Branded Jardiance (Boehringer Ingelheim/Lilly) or licensed generic in original sealed packaging from a reputable pharmacy.
Consistent tablet appearance
10 mg pale yellow round tablet, 25 mg pale yellow oval tablet (Jardiance branding). Generic shapes vary but should match the dispensed image.
International generic variation
Bioavailability across generics is generally tight (~99% f) but track effect if you switch sources.
Unbranded blister or compound
Counterfeit risk on international gray-market sales. Compounded SGLT2 inhibitors are not FDA-sanctioned and should be avoided.
What to Expect
- Week 1Tolerability and dose-response.
- Week 2-4Early effect window.
- Week 4-8Peak benefit assessment.
- Week 8+Cycle decision point.
Side Effects & Safety
- Common (>5%):
- Genitourinary fungal infections (women ~5-10%, men ~2-5%) — vulvovaginal candidiasis, balanitis. Topical antifungal usually resolves; recurrent → consider discontinuation.
- UTI (~5-9%) — modest elevation over baseline.
- Increased urination, thirst.
- Mild weight loss (intended for some).
- Less common (1-5%):
- Volume depletion symptoms (orthostatic hypotension, dizziness) — especially in elderly or diuretic users.
- Mild eGFR dip (~3-5 mL/min) in first 2-4 weeks; reverses, considered hemodynamic not nephrotoxic.
- Hyperkalemia (rare; usually in setting of ACEi/ARB/MRA stacking).
- Hypoglycemia (rare as monotherapy; risk rises with insulin/sulfonylurea stacking).
- Dyslipidemia: small LDL-C rise (~3-5 mg/dL), small HDL-C rise (~2 mg/dL); net CV effect favorable per trials.
- Rare-serious (<1% but worth knowing):
- Euglycemic diabetic ketoacidosis — class-wide risk. Ketones rise without protective hyperglycemia, so DKA can present at near-normal glucose. Triggers: prolonged fasting, ketogenic diet, severe illness, surgery, insulin-pump failure, alcohol binge. Rate ~0.1% in T2D, higher (~1-2%) in T1D off-label use. For a fighter who fasts/cuts weight + does ketogenic phases, this is the main concern. Hold drug 3+ days before any prolonged fast or cut.
- Fournier's gangrene (necrotizing fasciitis of the perineum) — rare but potentially fatal; FDA boxed warning class-wide. Characterized by severe genital pain + rapid swelling + fever. Emergent surgical care required.
- Acute kidney injury — usually in volume-depleted settings or contrast administration. Hold drug periprocedurally.
- Lower-limb amputation signal — observed with canagliflozin (CANVAS trial); empagliflozin in EMPA-REG showed no signal, and current FDA label does not include this warning. Class-wide signal historically; monitor.
- Bone fracture — canagliflozin signal again; empagliflozin EMPA-REG showed no signal.
- Specific watch periods:
- First 4 weeks: GU infection risk peak.
- First 2-4 weeks: volume contraction symptoms (orthostatic) — adjust diuretics if relevant.
- Any hospitalization, surgery, severe illness, prolonged fast, or ketogenic diet: HOLD drug 3+ days before, restart only when eating normally.
- Annual eGFR monitoring on chronic use.
References
Zinman et al., 2015 — NEJM: Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME)
landmark CV mortality trial
View StudyPacker et al., 2020 — NEJM: Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (EMPEROR-Reduced)
HFrEF trial
View StudyAnker et al., 2021 — NEJM: Empagliflozin in Heart Failure with a Preserved Ejection Fraction (EMPEROR-Preserved)
first HFpEF positive trial
View StudyEMPA-KIDNEY Collaborative Group, 2023 — NEJM: Empagliflozin in Patients with Chronic Kidney Disease
CKD trial
View StudyWanner et al., 2016 — NEJM: Empagliflozin and Progression of Kidney Disease in T2D
EMPA-REG renal substudy
View StudyInzucchi et al., 2018 — Diabetes Care: How Does Empagliflozin Reduce CV Mortality?
mediation analysis
View StudyFerrannini et al., 2016 — Diabetes Care: Shift in Substrate Utilization
ketogenesis mechanism
View StudyCherney et al., 2014 — Circulation: Renal Hemodynamic Effects
tubuloglomerular feedback
View StudyGoldenberg et al., 2016 — review on SGLT2i and euglycemic DKA
Latest research
- rctEMPA-KIDNEY — Empagliflozin in chronic kidney disease (NEJM)6,609 CKD patients with/without diabetes; 28% reduction in kidney disease progression or CV death over median 2 years. Broadest CKD signal of any SGLT2i; FDA expanded indication 2023.
- rctEMPEROR-Preserved — Empagliflozin in HFpEF (NEJM)First HFpEF trial to show benefit. n=5,988; 21% reduction in primary composite (CV death + HF hospitalization). Paradigm-shifting — HFpEF previously had no proven disease-modifying therapy.
- rctEMPEROR-Reduced — Empagliflozin in HFrEF (NEJM)n=3,730; 25% reduction in CV death + HF hospitalization regardless of diabetes status. Established HF as an independent indication; FDA expanded label 2021.
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.